Navigation Links
Doctors Biased Against Drug Company Research, Study Finds
Date:9/19/2012

By Barbara Bronson Gray
HealthDay Reporter

WEDNESDAY, Sept. 19 (HealthDay News) -- Physicians are less likely to trust even top-notch clinical research if it is funded by a pharmaceutical company, a new study suggests.

The researchers found that doctors downgraded their perception of research when told it was industry-funded, whether or not the studies were rigorously done or of high quality.

Although attention to potential sources of bias is important, such skepticism can reduce the acceptance of valuable new information critical to advancing health care, the researchers said.

"The issue is, it could be a problem if the findings of high-quality research aren't being implemented," said Dr. Aaron Kesselheim, lead author of the study and assistant professor of medicine at Harvard Medical School in Boston.

The study was published Sept. 20 in the New England Journal of Medicine.

Dr. Jeffrey Drazen, the journal's editor-in-chief and a professor of medicine at Harvard, said the validity of a research paper should be based solely on the quality of the research -- how the study was designed, conducted and analyzed -- not by the funding source. "Rigor eliminates bias," he said.

"One would think that the translation of research findings into clinical actions would depend solely on the importance of the research question and the quality of the data used to answer it, but this assumption is not entirely true," Drazen said in an editorial accompanying the research.

Pharmaceutical companies sponsor a large proportion of clinical trials of new treatments, the researchers noted.

Over the past 10 years or so, any financial support by drug makers has been noted in papers published in most medical research publications, Drazen explained. Some journals even include disclosures in the published abstracts of the studies -- short summaries that are widely read.

Such disclosures have been based on the assumption that when industry has a financial stake in the outcome of research, the study results can be biased to favor the source of the financial support.

"There were a number of egregious examples of bad behavior in the past, widely reported in the press," Drazen said. "So some people immediately think, 'If it's a drug company there must be something hidden here.'"

Kesselheim said he and his co-authors set out to better understand the impact that the disclosures were having on physician interpretation and practice.

"We asked ourselves, What would be ideal? And we decided it would be good if physicians took these disclaimers into account in studies of poor quality, but maybe not with the strong studies," Kesselheim said. "We wondered if physicians would moderate their responses when disclaimers were present."

The researchers developed 27 abstracts describing hypothetical research studies looking at three made-up drugs for three diseases: diabetes, hyperlipidemia (high blood fat levels) and angina pectoris (chest pain due to a lack of oxygen to the heart).

They also randomly varied the funding sources. One abstract listed the U.S. National Institutes of Health as the sponsor, another listed a fictitious drug company and a third said there was no external source of support.

More than 500 randomly selected internists were given three abstracts to review. The internists answered questions about the evidence presented in the research and how willing they would be to prescribe the drug based on the study. The physicians put more faith in the best-done studies, and 54 percent perceived the level of study rigor accurately.

But disclosure of industry funding, as compared with no disclosure, led physicians to downgrade the rigor of a trial, decrease their confidence in the study results and reduce their willingness to prescribe the drugs.

Physicians were half as willing to prescribe drugs studied in industry-funded trials as they were to prescribe drugs evaluated in NIH-sponsored trials.

Kesselheim said he thinks it's reasonable to be skeptical of research but it's important to move beyond that skepticism when the message from the studies is clear.

To increase the confidence physicians have in research supported by drug companies, Kesselheim said pharmaceutical companies should make all the data they submit to the U.S. Food and Drug Administration transparent and accessible by the public. Currently, he said, the information is provided only in the form of a summary statement.

Drazen expressed concern for the people who join clinical trials. "It's so important to continue to participate in research regardless of who is supporting it," he said. "And physicians should know these people earn our respect and we owe them the courtesy of acting on the findings when the research is solid."

More information

The U.S. National Institutes of Health has more about clinical trials.

SOURCES: Jeffrey Drazen, M.D., editor-in-chief, New England Journal of Medicine, professor of medicine, Harvard Medical School, Boston; Aaron Kesselheim, M.D., J.D., M.P.H., assistant professor of medicine, Harvard Medical School, Boston; New England Journal of Medicine, Sept. 20, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cancer Survivors Prefer to Stay With Cancer Doctors: Study
2. Doctors who perform abortions are compelled by conscience, just like those who refuse
3. Few Doctors Discuss Exercise With Cancer Patients: Study
4. Worlds largest meeting of ear, nose, and throat doctors
5. Doctors Who Self-Refer to Radiation Clinics Add to Patients Burden: Study
6. Many U.S. Doctors Have Symptoms of Burnout: Survey
7. With Very Sick Infants, Doctors and Parents Often Miscommunicate
8. Nurses as effective as doctors in treatment of HIV patients
9. Doctors can now detect hard-to-diagnose prostate cancer
10. Humanities mini-courses for doctors sharpen thinking and creativity
11. Doctors often dont disclose all possible risks to patients before treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology: